Drug Approval | May 12, 2022
OvaCis rapid test to detect ovarian cancer gets CE mark
Revolutionary ovarian cancer rapid test available Q4 2022
Revolutionary ovarian cancer rapid test available Q4 2022
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
The partners also aim to expand their work to Latin America for the first time
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
Lupin recognized the need to digitize more applications, improve scalability, decrease risk of security breaches and eliminate critical data loss
Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions
Subscribe To Our Newsletter & Stay Updated
